NICE backs Bayer's Xarelto in new stroke and heart attack pr...

Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.

Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.

FDA clears Bayer’s Gadavist as first contrast agent for card...

Bayer may merge animal health unit with Elanco; report

Bayer/J&J eye new paediatric use for anticoagulant Xarelto

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagul

Bayer begins phase 3 trial testing aflibercept in infant bli...

Bayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants.